Navigation Links
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Date:3/7/2008

ngs, interim results of preclinical or clinical studies do not necessarily predict their final results, and acceptable results in early studies might not be obtained in later studies. Drug candidates in the later stages of clinical development may fail to show the desired safety and efficacy traits despite positive results in initial clinical testing.

Additionally, as indicated in previous filings, there can be no assurance that the results from the Sulonex Phase 3 study will track the data from the pilot Collaborative Study Group Phase 2 study or the DiNAS Phase 2 study. Results from these earlier Sulonex studies may not be indicative of results from future clinical trials and the risk remains that the pivotal program for Sulonex may generate efficacy data that will be insufficient for the approval of the drug, or may raise safety concerns that may prevent approval of the drug.

Some of the statements included in this press release anticipating future clinical and business prospects for our lead drug candidate Sulonex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: if, upon final analysis, it is determined that all trials of Sulonex should be terminated, our ability to successfully adjust our strategy and reduce our operating expenses in order to properly support the trials of our other drug candidates; if, upon final analysis of the Phase 3 data, it is determined that dosing should continue in the Phase 4 study, our ability to complete enrollment into the Phase 4 study on the timetable previously set for completion of Phase 4; our ability to complete cost- effective clinical trials or meet anticipated development timelines for the other drug candidates in our pi
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ANGELES , FARUM, Denmark and ... On July 31, 2015 the US Food and ... the treatment of Major Depressive Disorder in adult patients who ... in the current episode. TMS is a non-invasive technique for ... in patients suffering from Major Depressive Disorder. The procedure has ...
(Date:8/28/2015)... ANDOVER, Massachusetts and LONDON , ... driven approach seamlessly ... health continuum improving outcomes and ... Philips  (NYSE: PHG AEX: PHIA) today announced its presence ... its latest cardiology solutions, including Heart Model A.I. , EchoNavigator ...
(Date:8/27/2015)... -- Biosimilars are not generics and the Biologics ... Drug Administration (FDA) for recognizing that each biosimilar ... issued today. The FDA,s draft guidance on nonproprietary ... for biological products to bear a nonproprietary name ... the agency,s thinking that "there is a need ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... 15, 2012  Fluke Biomedical announced today the newest ... quality-assurance testing and troubleshooting tools, the SPOT ... 15-second preventive maintenance (PM) test for SpO2 patient ... the fastest SpO2 functional tester ever achieved by ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced ... other conditions, shares of its common stock in an underwritten public ... the offering may be completed, or as to the actual size ... and Piper Jaffray & Co. are acting as joint book-running managers ...
Cached Medicine Technology:Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester 2Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock 4
(Date:8/28/2015)... ... 2015 , ... Northridge dentists Dr. Elyson and Dr. Assili are ... can currently receive a one hour treatment of this teeth whitening option. Zoom ... number of unique features that can turn teeth up to nine shades whiter. Effective ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout ... go deep sea diving. The act of recreational diving exposes the body ... reasons, it is vital that all recreational and professional divers undergo regular comprehensive ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Database have added comprehensive information on two new duals programs: Rhode Island ... 2015 launch; and Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... External Counterpulsation, ... Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with a ... Fit Clinic has been in business since 2007 helping people prevent and reverse ...
(Date:8/28/2015)... ... August 28, 2015 , ... A complimentary webinar offered ... Medicare & Medicaid Services’ (CMS) proposal to mandate bundled payments through the ... “Get Ready for Game Day: Comprehensive Care for Joint Replacement,” takes place at 12 ...
Breaking Medicine News(10 mins):Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3
... manufacturer, Compellis Pharmaceuticals, has been granted the PATENT ... //entitled "Inhibition of olfactory neurosensory function to treat ... biopharmaceutical company focusing more on developing novel mechanism-based ... company describes CP404 as "therapeutic platform for treating ...
... common form of brewer's yeast, University of Wisconsin-Madison researchers ... allow it to act as a master regulatory switch ... when malfunctioning in humans, may contribute to serious neurological ... issue of the journal Molecular Cell, shows how a ...
... years old- are as capable as teen-agers in handling ... them as it is more comfortable during activities like ... contact lenses to children until they are at least ... of optometry at Ohio State University. “But we found ...
... cultural or linguistic isolation, young Hispanic women and elderly ... attempting or committing suicide, mental health experts have warned. ... cultural and linguistic isolation, the stress of immigration and ... advocates who attended a hearing in Lower Manhattan on ...
... commissioned a specialty outpatient clinic for patients// with liver-related ... ,This Clinic, besides providing advanced therapeutic options to ... will also focus on preventive measures - said S. ... provision for conducting research in hepatology too – he ...
... President, Dr Choong-Siew Yong, today said the AMA’s ... program has been boosted by the findings of ... Prevention Project. ,The report, released today, demonstrated ... reduced difficult behaviour, and strengthened family relationships. ...
Cached Medicine News:Health News:From a Lowly Yeast, Researchers Divine a Clue to Human Disease 2Health News:Contact Lenses For Younger Children Also 2Health News:Contact Lenses For Younger Children Also 3
... 50 Urine Chemistry Analyzer is designed for use ... time for technicians, allowing them to be more ... It has a throughput of 50 strips per ... results, which may be downloaded to a computer ...
... collection under vacuum process makes the ... reduction. ,The Optivac® Vacuum Mixing ... of continuous improvement since its original ... a consistently high-quality, homogenous cement, with ...
... 35 years, Palacos® Bone Cement has ... standard in cemented arthroplasty. Palacos® is ... gentamicin, providing an antibiotic loaded bone ... second stage of a two-stage revision ...
Occu-Flo Plugs Offer: , Easy Insertion , A polished, smooth, transparent finish which creates immediate patient comfort and adaptation , High tolerance by patients , No discomfort should removal be ...
Medicine Products: